Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Q2 Results 2026 (FY27): Guides 10–20% Revenue Growth
Q2 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹16,199Cr
- +11.9% YoY
- Net profit
- ₹1,995Cr
- −36.2% YoY
- Margin
- 29%
- −2 pp YoY
Guidance rank: #86 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
2 of 3 strong
The short version
India business saw strong 17.3% sales growth in Q2 FY27, with volume growth at 6.7%, outperforming the Indian Pharmaceutical Market (IPM) growth of 1.8%. Sun Pharma reported Q2 FY27 sales growth of 11.8% YoY with gross margin improvement.
From Sun Pharmaceutical Industries Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Sun Pharmaceutical Industries' revenue grow in the September 2026 quarter?
- India business saw strong 17.3% sales growth in Q2 FY27, with volume growth at 6.7%, outperforming the Indian Pharmaceutical Market (IPM) growth of 1.8%. Growth is broad-based across 12 major therapy areas driven by brand building, scientific promotion, expanded field force, and increased prescribers. (Q2 FY27, Pages 5, 13, 15)
- (Page 12)
- US business grew quarter-on-quarter by 6.5%, supported by 5 generic product launches; Ilumya specialty drug growth to stabilize and improve over next quarters due to new psoriatic arthritis indication and interventions. (Pages 5, 7)
2 more points from Sun Pharmaceutical Industries Ltd's call on revenue
Create a free account to keep reading this call
What happened to Sun Pharmaceutical Industries' margins in Q2 FY27?
See what Sun Pharmaceutical Industries Ltd said on profitability & margins — free account, 30 seconds.
What capex is Sun Pharmaceutical Industries planning?
2 more points from Sun Pharmaceutical Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sun Pharmaceutical Industries raising money or cutting debt?
See what Sun Pharmaceutical Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Sun Pharmaceutical Industries' order book?
2 more points from Sun Pharmaceutical Industries Ltd's call on order book
Create a free account to keep reading this call
Sun Pharmaceutical Industries Ltd — Quarterly revenue & net profit
Sun Pharmaceutical Industries Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 16,199 | 14,478 | +11.9% | 15,300 | +5.9% |
| Operating profit (EBITDA) | 4,744 | 4,527 | +4.8% | 4,418 | +7.4% |
| Operating margin | 29% | 31% | -2 pp | 29% | 0 pp |
| Profit before tax | 3,159 | 4,168 | -24.2% | 4,099 | -22.9% |
| Net profit (PAT) | 1,995 | 3,125 | -36.2% | 2,901 | -31.2% |
| EPS (₹) | 8.29 | 13.00 | -36.2% | 12.06 | -31.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹16.2K Cr, net profit ₹2.0K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharmaceutical Industries's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Ipca Laboratories (Q2 FY27)
Volume-led growth in pain segment is around 8-9%, with price growth at 4-4.5%. Key concall takeaways from Ipca Laboratories Ltd's Q2 FY27 earnings call — and…
- Gland Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). Key investor presentation takeaways from Gland Ph
- OneSource Specialty Pharma (Q2 FY27)
. Key concall takeaways from OneSource Specialty Pharma Ltd's Q2 FY27 earnings call — and how it ranks against sector peers.
- Supriya Lifescience (Q2 FY27)
Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Key investor presentation takeaways from Supriya L
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharmaceutical Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharmaceutical Industries Ltd Q2 FY27 results?
India business saw strong 17.3% sales growth in Q2 FY27, with volume growth at 6.7%, outperforming the Indian Pharmaceutical Market (IPM) growth of 1.8%. Sun Pharma reported Q2 FY27 sales growth of 11.8% YoY with gross margin improvement.
What is Sun Pharmaceutical Industries Ltd share price analysis?
Sun Pharmaceutical Industries Ltd currently shows a below-average growth signal. The stock trades at a P/E of 35.7 with a market cap of ₹438,838 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sun Pharmaceutical Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.